NXN 188

Drug Profile

NXN 188

Alternative Names: NXN-188

Latest Information Update: 24 Jun 2015

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator NeurAxon
  • Class Small molecules
  • Mechanism of Action Calcitonin gene-related peptide antagonists; Nitric oxide synthase inhibitors; Serotonin receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Migraine

Most Recent Events

  • 08 Jun 2015 Phase-II development of an oral formulation of NXN 188 is ongoing in the US, Canada and Denmark
  • 01 Jan 2015 NXN 188 licensed to Knight Therapeutics in Canada, Israel, South Africa and Russia
  • 31 Aug 2012 Preclinical study pharmacodynamics data in Migraine presented at the 14th World Congress on Pain (WCP-2012)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top